Aspirin under fire: Aspirin use in the primary prevention of coronary heart disease

被引:8
|
作者
Miller, MG
Lucas, D
Papademetriou, V
Elhabyan, AK
机构
[1] Charleston Area Med Ctr, Hlth Educ & Res Inst, Ctr Clin Sci Res, Charleston, WV 25304 USA
[2] Solvay Pharmaceut Inc, Med Serv Dept, Allison Pk, PA USA
[3] W Virginia Univ, Sch Med, Charleston, WV 25304 USA
[4] Vet Affairs Med Ctr, Dept Med Hypertens & Cardiovasc Res, Washington, DC 20422 USA
[5] Georgetown Univ, Washington, DC USA
来源
PHARMACOTHERAPY | 2005年 / 25卷 / 06期
关键词
aspirin; coronary heart disease; CHD; primary prevention; risk prediction;
D O I
10.1592/phco.2005.25.6.847
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The issue of aspirin use in the primary prevention of cardiovascular disease is still debated because of conflicting opinions on risks versus benefits. Recently a United States Food and Drug Administration (FDA) panel rejected the approval of aspirin in the setting of primary prevention in moderate-risk patients. However, the United States Preventive Services Task Force recommends that clinicians discuss aspirin therapy with patients at increased risk for having a future coronary event. During the past 15 years, many large randomized trials have specifically addressed this issue and helped shape the decisions of the FDA panel and the Preventive Services Task Force. These trials lend a handful of experiences and results, with no clear recommendations for antiplatelet therapy in the setting of primary prevention of coronary heart disease (CHD). Recently, trial results have been assimilated into practical tools for risk stratification to guide aspirin use in this setting. An overview and critical evaluation of the work performed thus far is provided in order to lend insight into the ongoing debate and, through use of the Framingham CHD risk prediction score sheets, to better equip practitioners faced with the decision of giving aspirin to "relatively" healthy individuals for CHD primary prevention.
引用
收藏
页码:847 / 861
页数:15
相关论文
共 50 条
  • [1] Primary prevention of coronary heart disease with aspirin
    Kübler, W
    Darius, H
    ZEITSCHRIFT FUR KARDIOLOGIE, 2005, 94 : 66 - 73
  • [2] Aspirin use for the primary prevention of coronary heart disease in older adults
    Rodondi, Nicolas
    Vittinghoff, Eric
    Cornuz, Jacques
    Butler, Javed
    Ding, Jingzhong
    Satterfield, Suzanne
    Newman, Anne B.
    Harris, Tamara B.
    Hulley, Stephen B.
    Bauer, Douglas C.
    AMERICAN JOURNAL OF MEDICINE, 2005, 118 (11): : 1288.e1 - 1288.e9
  • [3] Primary prevention of coronary heart disease with aspirin
    Kübler, W
    ZEITSCHRIFT FUR KARDIOLOGIE, 2004, 93 : 33 - 36
  • [4] Aspirin use for the primary prevention of coronary heart disease:: A population-based study in Switzerland
    Rodondi, Nicolas
    Cornuz, Jacques
    Marques-Vidal, Pedro
    Butler, Javed
    Hayoz, Daniel
    Pecoud, Alain
    Paccaud, Fred
    Waeber, Gerard
    Vollenweider, Peter
    PREVENTIVE MEDICINE, 2008, 46 (02) : 137 - 144
  • [5] Aspirin in primary prevention of iscemic heart disease
    Preobrazhensky, DV
    Sidorenko, BA
    Malysheva, NV
    Trushko, VV
    KARDIOLOGIYA, 2002, 42 (04) : 91 - 95
  • [6] Preventing Cardiovascular Disease in Patients with Diabetes: Use of Aspirin for Primary Prevention
    Desai, Dhaval
    Ahmed, Haitham M.
    Michos, Erin D.
    CURRENT CARDIOLOGY REPORTS, 2015, 17 (03) : 1 - 9
  • [7] Aspirin for primary prevention of cardiovascular disease in Japan
    Morimoto, Takeshi
    Matsui, Kunihiko
    INTERNAL MEDICINE, 2007, 46 (15) : 1281 - 1281
  • [8] Aspirin for primary prevention of cardiovascular disease
    Nansseu J.R.N.
    Noubiap J.J.N.
    Thrombosis Journal, 13 (1)
  • [9] Polygenic risk, aspirin, and primary prevention of coronary artery disease
    Yu, Chenglong
    Natarajan, Pradeep
    Patel, Aniruddh P.
    Bhatia, Harpreet S.
    Khera, Amit, V
    Neumann, Johannes T.
    Tsimikas, Sotirios
    Wolfe, Rory
    Nicholls, Stephen J.
    Reid, Christopher M.
    Zoungas, Sophia
    Tonkin, Andrew M.
    Mcneil, John J.
    Lacaze, Paul
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2024,
  • [10] Aspirin for primary prevention of coronary heart disease: Using the Framingham Risk Score to improve utilization in a primary care clinic
    Romero, Steven C.
    Dela Rosa, Kristina M.
    Linz, Peter E.
    SOUTHERN MEDICAL JOURNAL, 2008, 101 (07) : 725 - 729